United Therapeutics' 15min chart shows MACD Death Cross and Bollinger Bands narrowing.

Based on the 15-minute chart analysis of United Therapeutics, a significant indicator has been triggered - the MACD Death Cross. Additionally, the Bollinger Bands have narrowed at 06/27/2025 13:15. These technical indicators suggest that the stock price has the potential to continue trending downward, with a notable decrease in the magnitude of stock price fluctuations.

United Therapeutics Corp (UTHR) has been making waves in the biotechnology sector with its innovative approaches to addressing unmet medical needs. However, recent technical indicators suggest a potential downward trend in the stock price. The 15-minute chart analysis has triggered a MACD Death Cross and the Bollinger Bands have narrowed, indicating a potential decrease in stock price fluctuations and a continued downward trend.

On June 24, 2025, Nilda Mesa, a Director at United Therapeutics Corp, sold 645 shares of the company [1]. This transaction, along with the overall insider selling activity, has raised some concerns among investors. Over the past year, Mesa has sold a total of 1,390 shares and has not purchased any shares. The insider transaction history shows 0 insider buys and 87 insider sells over the same timeframe [1].

Despite these technical concerns, United Therapeutics has made a significant breakthrough in the field of organ transplantation. The company, in collaboration with Intermountain Health, has successfully performed the world’s first treatment using a bioengineered liver support system, the miroliverELAP system [3]. This innovative procedure was executed at Intermountain Medical Center in Murray, Utah, on a patient who could not receive a liver transplant. The miroliverELAP system involves a bioengineered liver made from a decellularized porcine scaffold infused with human cells. This breakthrough represents a significant stride in addressing the shortage of transplantable organs and offers alternative solutions for liver support [3].

As of the date of the recent transaction, shares of United Therapeutics Corp were trading at $289.99, giving the stock a market cap of $12.899 billion [1]. The company's price-earnings ratio is 11.41, which is lower than the industry median of 23.335 and also lower than the company’s historical median price-earnings ratio. With a price of $289.99 and a GuruFocus Value of $365.80, United Therapeutics Corp has a price-to-GF-Value ratio of 0.79, indicating that the stock is modestly undervalued based on its GF Value [1].

While the technical indicators suggest a potential downward trend, the clinical breakthrough with the miroliverELAP system could provide long-term growth opportunities for United Therapeutics. Investors should closely monitor the company's stock price and technical indicators, as well as its progress in clinical trials and market developments.

References:

[1] https://www.gurufocus.com/news/2946627/insider-sell-nilda-mesa-sells-shares-of-united-therapeutics-corp
[3] https://www.gurufocus.com/news/2941582/united-therapeutics-and-intermountain-health-announce-the-first-patient-treated-with-external-liver-support-using-a-bioengineered-liver-uthr-stock-news